transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Pancreatic Cancer. Experimental and Clinical Studies

Författare och institution:
David Ljungman (Institutionen för kliniska vetenskaper, sektionen för kirurgi och kirurgisk gastroforskning, Avdelningen för kirurgi)
Antal sidor:
University of Gothenburg
Datum för examination:
Tidpunkt för examination:
Fredagen den 11 oktober 2013, kl. 9.00, Stora aulan, Centralkomplexet, Östra sjukhuset
Prof. Jörgen Larsson, Verksamhetschef Innovationsplatsen Karolinska Universitetssjukhuset, Enhetschef Enheten för kirurgi, CLINTEC, KI
Sammanfattning (abstract):
Background: Pancreatic cancer is one of the most lethal of known cancers and the only treatment with possibility of cure is surgery. The costs associated with treatment of pancreatic cancer are reputably high, both in terms of morbidity and financially. To reinforce decision making there is a need to assess the costs and benefits of current treatment. Furthermore, the incitements to develop therapeutic alternatives and biologically characterize individual tumors are considerable. Methods: Evaluation of effects of proteasome inhibition on intracellular signaling systems using in vitro and in vivo experiments. Estimation of achieved utilities and direct healthcare costs based on a clinical cohort. Assessment of prognostic significance of structural genomic aberrations using comparative genomic hybridization and single nucleotide polymorphism analysis on resected tumor tissue. Results: Proteasome inhibition activated an antiapoptotic and mitogenic therapy resistance response in several mediators (EGFR, JNK, ERK and PI3K/Akt) and the inhibition of Akt and JNK increased the tumoricidal effect of proteasome inhibitors. The activation was EGFR independent and the increased cell death was not NF-κB mediated. Patients undergoing resections with curative aim and patients receiving palliative care both experienced decreased health related quality of life in all SF-36 dimensions at diagnosis, without apparent improvement over time. The cost of treatment for patients undergoing surgery was two times the cost for the palliative patients (€50,950 vs. €23,701). Interestingly, already after one year the achieved QALY was twice as large in the resection group (0.48 vs. 0.20) resulting in cost per QALY neutralization between groups. DNA copy number alterations were seen in 2p11.2, 3q24, 8p11.22, 14q11.2 and 22q11.21. No convincing specific aberrations of prognostic value were found. Short survival was however responsible for 67% of total copy number variation and associated with significantly more amplifications, possibly related to alterations in chromosome 2, 11 and 21. Conclusions: Proteasome inhibition is a promising adjunct in horizontal targeted therapy regimens and the effect may be potentiated by simultaneous inhibition of signaling systems. Costs for pancreatic cancer surgery are comparable to other major healthcare interventions and long term survival in a few is effectively increasing cost-effectiveness on patient group basis. DNA from patients with poor prognosis contains more amplifications and seems to be generally more degenerated possibly indicating a greater genomic instability. The pancreatic cancer mutational profile is displaying vast inter-individual heterogeneity and most mutations are probably passengers.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Klinisk medicin ->
Cancer och onkologi
Klinisk medicin ->
Pancreatic neoplasms, Proteasome inhibitors, Apoptosis, Intracellular signaling peptides and proteins, Epidermal growth factor receptor, Pancreaticoduodenectomy, Cost and cost analysis, Quality-adjusted life years, Copy number variations, Comparative genomic hybridization
Postens nummer:
Posten skapad:
2013-09-02 08:30
Posten ändrad:
2014-01-13 10:26

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007